The World Health Organization (WHO) classification system divides glioma into low-grade (I-II) and high-grade (III-IV) based on the absence or presence of anaplastic features and histological characteristics with molecular features, including isocitrate dehydrogenase 1 (IDH1) mutation and 1p/19q codeletion [1, 2]. Here, IDH1 is linked to glioma.